Loading...
•
Dec 31, 2022
Repare Therapeutics Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Repare Therapeutics reported fourth-quarter financial results, featuring revenue from collaboration agreements of $18.2 million and a net loss of $31.7 million. The company highlighted progress in its pipeline, including the collaboration with Roche on camonsertib and the Fast Track designation for RP-6306.
Advanced camonsertib in partnership with Roche, with initial data expected in H1 2023.
Reported initial Phase 1 clinical data for RP-6306 as a monotherapy for advanced solid tumors in the first half of 2023, and combination therapy data in Q4 2023.
FDA granted Fast Track designation to RP-6306 in combination with gemcitabine for platinum-resistant ovarian cancer.
Initiated IND-enabling studies for a small molecule against an undisclosed target, with potential clinical entry in late 2023 or early 2024.
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Repare Therapeutics anticipates a productive 2023, with early clinical readouts for camonsertib and RP-6306 expected in the first half of the year and plans to expand its pipeline.
Positive Outlook
- Initial data from Phase 1/2 trials of camonsertib in combination with PARP inhibitors expected in H1 2023.
- Initial data from the Phase 1/2 TRESR trial evaluating camonsertib in combination with gemcitabine expected in summer or fall 2023.
- Initial Phase 1 clinical data for RP-6306 as a monotherapy expected in H1 2023.
- Initial Phase 1 clinical data for RP-6306 as a combination therapy expected in Q4 2023.
- Initiation of IND-enabling studies for a small molecule against an undisclosed target in H1 2023.
Challenges Ahead
- Prioritization of other Polθ inhibiting compounds may delay clinical entry for a Polθ inhibitor to 2024.
- Macroeconomic conditions, including the COVID-19 pandemic and rising inflation, could impact the business.
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
- Clinical trial site activation or enrollment rates that are lower than expected.
- Changes in the regulatory environment and the uncertainties of the regulatory approval process.